Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
85 participants
INTERVENTIONAL
2003-07-31
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
NCT00242840
Accelerated ART Initiation for PWHIV Who Are Out of Care
NCT06374758
Fuzeon Viral Decay Pilot Study
NCT00334022
Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
NCT02121795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fosamprenavir
Telzir®
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must belong to one of the following populations:
1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
2. Subjects who already receive amprenavir (Agenerase®)
3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
ViiV Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
ViiV Healthcare
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Aarau, , Switzerland
GSK Investigational Site
Basel, , Switzerland
GSK Investigational Site
Bern, , Switzerland
GSK Investigational Site
Bruderholz, , Switzerland
GSK Investigational Site
La Chaux-de-Fonds, , Switzerland
GSK Investigational Site
Lausanne, , Switzerland
GSK Investigational Site
Lucerne, , Switzerland
GSK Investigational Site
Lugano, , Switzerland
GSK Investigational Site
Sankt Gallen, , Switzerland
GSK Investigational Site
Zurich, , Switzerland
GSK Investigational Site
Zurich, , Switzerland
GSK Investigational Site
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APV40005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.